Clinical Advances in Pulmonary Heart Disease
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiovascular Medicine".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 485
Special Issue Editors
2. National Pulmonary Hypertension Service, Royal Brompton Hospital, London SW3 6NP, UK
Interests: pulmonary hypertension; congenital heart disease; artificial intelligence
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pulmonary hypertension (PH) represents a rare and heterogeneous group of pulmonary vasculopathies defined by elevated mean pulmonary arterial pressure and pulmonary vascular resistance that leads progressively to right heart failure and premature death, if not early diagnosed and promptly treated. PH is haemodynamically defined as a mean pulmonary artery pressure > 20 mmHg and is classified into five distinct groups, taking into account the underlying condition, clinical and haemodynamic features PH can be attributed to a wide spectrum of underlying conditions, such as left heart disease, lung disease, pulmonary artery obstruction, but it can also be associated with drugs and toxins, connective tissue disease (CTD-PAH), HIV infection, portal hypertension (portal-PAH), congenital heart disease (CHD-PAH) and schistosomiasis or it can be idiopathic (IPAH) or heritable (HPAH). In the past 30 years, there was an increased research interest in the field of pathophysiology, diagnosis and targeted pulmonary arterial hypertension (PAH) therapies. New diagnostic modalities and algorithms were employed to detect PH early, while new drugs have been developed that target different pathophysiologic pathways aiming to increase life expectancy. In this Special Issue, we would like to invite original clinical and basic research, meta-analyses, and state-of-the-art reviews related to clinical advances in the whole spectrum of PH and pulmonary heart disease in general. We will be grateful to receive your submissions to move the field of PH forward.
Dr. Alexandra D. Arvanitaki
Dr. Stephen John Wort
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary heart disease
- pulmonary hypertension
- diagnosis
- treatment
- clinical advances
